Group 1 - The core viewpoint of the news is that Jieko Biotech's application for the marketing authorization of Ranibizumab injection has been accepted by the National Medical Products Administration, supported by Yidu Technology's comprehensive clinical research services [1][2] - Age-related macular degeneration (AMD) is a leading cause of blindness in individuals aged 50 and above, with a prevalence rate of 13.36% among those over 60 in China, and wet AMD (wAMD) accounting for 13.42% of cases, with a blindness rate of approximately 90% [1][2] - Yidu Technology has established a strong foundation for clinical research through its AI medical infrastructure, having processed over 6 billion authorized medical records and covering more than 4,000 hospitals, which supports the ongoing Phase III clinical trial [2][3] Group 2 - Yidu Technology's service capabilities are enhanced by its expertise in ophthalmology, allowing for precise management of trial specifications and risks associated with wAMD, resulting in a patient dropout rate of only 15% and a shortened project cycle [3] - The company has established strategic partnerships with renowned ophthalmology experts and institutions, demonstrating its commitment to collaborative development in the medical and research fields [3] - As of March 31, 2025, Yidu Technology has completed 411 clinical studies, including 275 real-world research projects, showcasing its extensive experience in clinical research [3]
医渡科技助力杰科生物雷珠单抗生物类似药申报上市